rs121913121
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM5PP3_StrongPP5_Very_Strong
The NM_000143.4(FH):c.320A>C(p.Asn107Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000752 in 1,461,812 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N107K) has been classified as Pathogenic.
Frequency
Consequence
NM_000143.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FH | NM_000143.4 | c.320A>C | p.Asn107Thr | missense_variant | 3/10 | ENST00000366560.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FH | ENST00000366560.4 | c.320A>C | p.Asn107Thr | missense_variant | 3/10 | 1 | NM_000143.4 | P1 |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD4 exome AF: 0.00000752 AC: 11AN: 1461812Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 727206
GnomAD4 genome ? Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 18, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as N64T; This variant is associated with the following publications: (PMID: 16029320, 26900816, 21445611, 23211287, 21630274, 16757530, 19939761, 15937070, 12761039, 29909963, 11865300, 34604083, 36777509, 24625422) - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jul 26, 2023 | For these reasons, this variant has been classified as Pathogenic. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on FH function (PMID: 11865300). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FH protein function. ClinVar contains an entry for this variant (Variation ID: 92455). This variant is also known as c.191A>C, p.Asn64Thr. This missense change has been observed in individuals with hereditary leiomyomatosis and renal cell cancer (PMID: 11865300, 15937070, 16757530, 21630274, 23211287, 24625422, 26900816). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces asparagine, which is neutral and polar, with threonine, which is neutral and polar, at codon 107 of the FH protein (p.Asn107Thr). - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 17, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 12, 2015 | - - |
Hereditary leiomyomatosis and renal cell cancer Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 2006 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jul 05, 2023 | This variant is considered likely pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 12761039, 16237213, 11865300, 31831373, 34604083]. Functional studies indicate this variant impacts protein function [PMID: 16237213,11865300, 16597677, 20109171]. This variant is expected to disrupt protein structure [Myriad internal data]. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Jan 17, 2017 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | Dec 17, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | research | Academic Department of Medical Genetics, University of Cambridge | Jan 26, 2018 | Application of AMCG guidelines 2015. Used other ClinVar submission evidence where relevant. Loss of heterozygosity in tumours or immunohistochemistry abnormalities considered functional evidence of pathogenicity. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 05, 2022 | The p.N107T pathogenic mutation (also known as c.320A>C), located in coding exon 3 of the FH gene, results from an A to C substitution at nucleotide position 320. The asparagine at codon 107 is replaced by threonine, an amino acid with similar properties. This alteration, designated as Asn64Thr or N64T, was identified in at least 12 apparently unrelated individuals from the UK who had multiple leiomyomata; in one of these families, the alteration segregated with disease in 16 affected relatives (Tomlinson I et al. Nat Genet. 2002 Apr;30(4):406-10; Alam N et al. Hum Mol Genet. 2003 Jun 1;12(11):1241-52). This alteration has been reported in additional individuals with cutaneous and/or uterine leiomyomas and/or renal cell carcinoma, some of whose tumors had loss of FH on immunohistochemical staining or FH loss-of-heterozygosity (Sanz-Ortega J et al. Am J Surg Pathol. 2013 Jan;37(1):74-80; Carvajal-Carmona L et al. J Clin Endocrinol Metab. 2006 Aug;91(8):3071-5; Wei M et al. J Med Genet. 2006 Jan;43(1):18-27; Udager AM et al. Am. J. Surg. Pathol. 2014 Apr;38:567-77; Trpkov K et al. Am. J. Surg. Pathol. 2016 Jul;40:865-75; Bardella C et al. J. Pathol. 2011 Sep;225:4-11). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at